Tomoverse Imaging Inc featured prominently at the EuroPCR 2026 conference in Paris, underscoring its focus on advanced cardiac CT imaging and interventional cardiology workflows. Co‑founder Pascal Thériault‑Lauzier led a session on optimal imaging projections for bifurcation percutaneous coronary intervention, framed as a peer‑to‑peer exchange with leading cardiologists.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s presence and on‑stage role signal deeper engagement with key opinion leaders in both structural heart and complex PCI segments, critical customer groups for imaging‑driven guidance tools. By emphasizing collaborative learning and “getting it right for patients,” Tomoverse is aligning its positioning with evidence‑based practice and clinical workflow optimization.
Across its communications, Tomoverse highlighted EuroPCR as a strategic venue for networking with interventional cardiologists, imaging specialists, and structural heart experts. Management appears focused on ecosystem building, including potential pilot collaborations, data‑generation opportunities, and integration of its solutions into routine PCI and structural heart workflows.
While no specific products, contracts, or revenue figures were disclosed, sustained visibility at a major European cardiovascular meeting may support future commercial traction. Stronger relationships with hospitals, device makers, and clinical decision‑makers could enhance Tomoverse’s long‑term competitive stance in the medtech and cardiac imaging markets.
Overall, the week’s news positions Tomoverse as an emerging player deepening its clinical ties and reinforcing its relevance in image‑guided coronary and structural heart interventions, laying groundwork for future validation and adoption rather than near‑term financial impact.